A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs I-131-Apamistamab (Primary) ; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms SIERRA
  • Sponsors Actinium Pharmaceuticals
  • Most Recent Events

    • 26 Jun 2018 According to an Actinium Pharmaceuticals media release, company announced that it has dosed the 38th patient in this study.The trials independent Data Monitoring Committee (DMC) will review the trial data at its next meeting, which has been scheduled for August
    • 28 Feb 2018 According to an Actinium Pharmaceuticals media release, company announced that it had amended the protocol of this trial to expand the number of salvage chemotherapy agents included in the control arm, and Stony Brook University as the 16th clinical trial site has been activated.
    • 27 Feb 2018 According to an Actinium Pharmaceuticals media release, the Company has successfully activated sixteen clinical trial sites in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top